Bill Text: IL HB3472 | 2025-2026 | 104th General Assembly | Introduced

---

Bill Title: Amends the Illinois Food, Drug and Cosmetic Act. Provides that any health care practitioner authorized by applicable law to issue prescriptions for Schedule II controlled substances shall, prior to issuing an initial prescription for a Schedule II controlled substance or any other opioid pain reliever during a course of treatment for acute or chronic pain shall discuss with the patient or the patient's parent or guardian, if the patient is under 18 years of age and is not an emancipated minor, the risks associated with the drugs being described. Provides that the discussion required by this provision shall take place before issuing an initial prescription, and again prior to issuing the third prescription during a course of treatment. Provides that the prescribing health care practitioner shall include a note in the patient's medical record that the patient or the patient's parent or guardian, as applicable, has discussed with the practitioner the risks of developing a physical or psychological dependence on the controlled dangerous substance and on alternative treatments that may be available. Provides that these provisions do not apply to prescriptions for a patient who is currently in an active treatment for cancer, receiving hospice care from a licensed hospice or palliative care provider, for a patient who is a resident of a long-term care facility, or to any medications being prescribed for use in the treatment of substance abuse or opioid dependence.

Sponsorship: Partisan Bill (Democrat 1)

Status: (Introduced - Dead) 2025-02-18 - Referred to Rules Committee [HB3472 Detail]

Download: Illinois-2025-HB3472-Introduced.html

---

104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB3472 Introduced , by Rep. Joyce Mason SYNOPSIS AS INTRODUCED:
410 ILCS 620/28 new
Amends the Illinois Food, Drug and Cosmetic Act. Provides that any health care practitioner authorized by applicable law to issue prescriptions for Schedule II controlled substances shall, prior to issuing an initial prescription for a Schedule II controlled substance or any other opioid pain reliever during a course of treatment for acute or chronic pain shall discuss with the patient or the patient's parent or guardian, if the patient is under 18 years of age and is not an emancipated minor, the risks associated with the drugs being described. Provides that the discussion required by this provision shall take place before issuing an initial prescription, and again prior to issuing the third prescription during a course of treatment. Provides that the prescribing health care practitioner shall include a note in the patient's medical record that the patient or the patient's parent or guardian, as applicable, has discussed with the practitioner the risks of developing a physical or psychological dependence on the controlled dangerous substance and on alternative treatments that may be available. Provides that these provisions do not apply to prescriptions for a patient who is currently in an active treatment for cancer, receiving hospice care from a licensed hospice or palliative care provider, for a patient who is a resident of a long-term care facility, or to any medications being prescribed for use in the treatment of substance abuse or opioid dependence.
LRB104 10976 RLC 21058 b
A BILL FOR
HB3472 LRB104 10976 RLC 21058 b
AN ACT concerning health.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 5. The Illinois Food, Drug and Cosmetic Act is
amended by adding Section 28 as follows:
(410 ILCS 620/28 new)
Sec. 28. Opioid patients right to know.
(a) Any health care practitioner authorized by applicable
law to issue prescriptions for Schedule II controlled
substances shall, prior to issuing an initial prescription for
a Schedule II controlled substance or any other opioid pain
reliever during a course of treatment for acute or chronic
pain shall discuss with the patient or the patient's parent or
guardian, if the patient is under 18 years of age and is not an
emancipated minor, the risks associated with the drugs being
described. The information discussed shall include, but is not
limited to:
(1) the risks of addiction and overdose associated
with opioid drugs and the dangers of taking opioid drugs
with alcohol, benzodiazepines, and other central nervous
system depressants;
(2) the reasons why the prescription is necessary;
(3) any alternative treatments available; and

HB3472 - 2 - LRB104 10976 RLC 21058 b
(4) any additional risks associated with the use of
the drugs being prescribed, specifically that opioids are
highly addictive, that there is a risk of developing a
physical or psychological dependence on the controlled
substance being prescribed, and that taking more opioids
than prescribed, or mixing the prescribed medication with
benzodiazepines, sedatives, or mixing opioids with alcohol
can result in fatal respiratory depression.
(b) The discussion required by subsection (a) shall take
place before issuing an initial prescription, and again prior
to issuing the third prescription during a course of
treatment.
(c) The prescribing health care practitioner shall include
a note in the patient's medical record that the patient or the
patient's parent or guardian, as applicable, has discussed
with the practitioner the risks of developing a physical or
psychological dependence on the controlled dangerous substance
and on alternative treatments that may be available.
(d) This Section does not apply to prescriptions for a
patient who is currently in an active treatment for cancer,
receiving hospice care from a licensed hospice or palliative
care provider, for a patient who is a resident of a long-term
care facility, or to any medications being prescribed for use
in the treatment of substance abuse or opioid dependence.